Today: 10 June 2026
Visa stock price at $320: what to watch before NYSE:V reopens Monday
1 March 2026
1 min read

Visa stock price at $320: what to watch before NYSE:V reopens Monday

NEW YORK, March 1, 2026, 11:41 a.m. EST — Market is closed

  • Visa climbed 1.09% Friday, wrapping up the session at $320.14 and notching a fourth straight day of gains.
  • U.S. inflation and jobs numbers are up next for the stock, posing another hurdle that could sway rate-cut expectations.
  • Traders are eyeing whether the rotation out of high-growth tech that started Friday will stick around as March arrives.

Visa Inc. climbed into the weekend, defying a more hesitant Wall Street. The payments giant stays in the spotlight with markets set to reopen Monday.

The stock’s status as a reliable “steady earner” is in focus, with markets swinging on headlines—think inflation numbers, rate moves, geopolitics. Anything that seems richly valued is taking a hit.

U.S. stocks edged lower Friday, as concerns about stretched valuations and the disruptive potential of artificial intelligence weighed on sentiment. Nvidia’s strong numbers weren’t enough to shore up chip stocks. “Now it’s time for a breather,” said Talley Leger, chief market strategist at The Wealth Consulting Group, referring to semiconductors after their recent surge. Reuters

Visa bucked the trend, rising with a handful of other financial stocks. Mastercard managed gains as well. But a number of major banks slipped, market data showed.

Inflation chatter picked up Friday after U.S. producer prices climbed 0.5% in January, with core numbers jumping the most since mid-2020. Economists flagged the report as a reason for the Federal Reserve to stay cautious on rate cuts. “We expect the Fed to remain on pause” in March, Nationwide’s Ben Ayers said. Paul Ashworth of Capital Economics noted the data showed tariff effects. Reuters

Visa investors are watching two things: rates and spending. Equity multiples can take a hit from a higher-for-longer policy. If there’s an actual drop in card spending, it will show up in payment volumes and cross-border activity — that’s card spending outside a customer’s home country, usually tracking with travel.

The setup has two sides. Should next week’s data come in softer, and rate-cut bets harden, sentiment could flip quickly—Visa’s Friday outperformance might fade into the background if investors start shedding risk across the board.

Coming up first: the U.S. February jobs report, scheduled for March 6 at 8:30 a.m. ET.

The U.S. February consumer price index lands March 11 at 8:30 a.m. ET, two business days after.

The Personal Income and Outlays report, set for release March 13 at 8:30 a.m. ET, carries the Fed’s inflation gauge of choice: the PCE price index.

Traders, looking past the latest numbers, have their focus set on the Fed’s March 17-18 meeting, watching for potential changes in the central bank’s rate guidance.

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing
Previous Story

Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing

GE Aerospace stock price near record high as supply-chain bottlenecks stay in focus
Next Story

GE Aerospace stock price near record high as supply-chain bottlenecks stay in focus

Go toTop